Scynexis (SCYX) Amortization of Deferred Charges (2013 - 2025)
Scynexis (SCYX) posted Amortization of Deferred Charges of $87000.0 for Q4 2025, up 12.99% on a QoQ basis from $77000.0 in Q1 2025, and up 108.79% year-over-year from $41669.1 in Q4 2024.
Scynexis (SCYX) Amortization of Deferred Charges (2013 - 2025) Analysis & Trends
Scynexis' Amortization of Deferred Charges history runs 12 years deep, the most recent figure standing at $87000.0 for Q4 2025.
- Quarterly Amortization of Deferred Charges rose 108.79% year-over-year to $87000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $87000.0 (up 270.59% YoY) and the FY2025 annual result came in at $326000.0, up 19.85% from the prior year.
- Amortization of Deferred Charges was $87000.0 for Q4 2025 at Scynexis, up from $77000.0 in the prior quarter.
- Across five years, Amortization of Deferred Charges topped out at $2.8 million in Q4 2023 and bottomed at -$990000.0 in Q4 2024.
- A 5-year average of $440000.0 and a median of $375000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges soared 706.12% — and 2024, when it plunged 135.04%.
- Scynexis' Amortization of Deferred Charges stood at $49000.0 in 2021, then surged by 706.12% to $395000.0 in 2022, then surged by 615.19% to $2.8 million in 2023, then plunged by 135.04% to -$990000.0 in 2024, then soared by 108.79% to $87000.0 in 2025.
- Business Quant data shows SCYX's Amortization of Deferred Charges at $87000.0 in Q4 2025, $77000.0 in Q1 2025, and -$990000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 88.88 Bn | 87.01 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.92 Bn | 32.18 Bn | 1.97 Bn |
| 3 | Zoetis | 32.31 Bn | 30.37 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.54 Bn | 23.48 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 20.53 Bn | 20.53 Bn | - |
| 7 | Viatris | 20.27 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.92 Bn | 16.61 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn |
| 10 | Scynexis | 24.05 Mn | -12.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 87,000.00 |
| Dec 31, 2025 | 87,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Mar 31, 2025 | 77,000.00 |
| Dec 31, 2024 | -990,000.00 |
| Dec 31, 2024 | -990,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Sep 30, 2024 | 441,000.00 |
| Jun 30, 2024 | 421,000.00 |
| Jun 30, 2024 | 421,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Mar 31, 2024 | 64,000.00 |
| Dec 31, 2023 | 2.83 Mn |
| Dec 31, 2023 | 2.83 Mn |
| Sep 30, 2023 | 360,000.00 |
| Sep 30, 2023 | 360,000.00 |
| Jun 30, 2023 | 2.00 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 255,000.00 |
| Mar 31, 2023 | 255,000.00 |